Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds.
Intellia Therapeutics Inc. (NTLA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 11,919,178 | $205,844,200 | -9% | 1.23% |
| 2. | Contrarius Investment Management Stephen Mildenhall | 5,889,936 | $101,719,195 | +280% | 4.6% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,746,674 | $47,435,060 | +3% | 0.34% |
| 4. | D E Shaw D. E. Shaw | 2,228,400 | $38,484,468 | +171% | 0.02% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 2,163,417 | $37,362,212 | +4% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.03 | 100,000 | $1,003,000.00 | 134,693 | 2025-08-20 | Filing | |
| $15.50 | 4,250 | $65,875.00 | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | $52,000.00 | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | $1,053,612.00 | 2,662,180 | 2016-05-11 | Filing | |
| $18.00 | 191,466 | $3,446,388.00 | 2,603,646 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.38 | 31 | $538.78 | 105,184 | 2025-10-01 | Filing | |
| $17.38 | 1,871 | $32,517.98 | 55,266 | 2025-10-01 | Filing | |
| $14.02 | 7,462 | $104,617.24 | 106,062 | 2025-07-23 | Filing | |
| $9.82 | 1,022 | $10,036.04 | 95,369 | 2025-07-01 | Filing | |
| $9.95 | 2,503 | $24,904.85 | 57,137 | 2025-07-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,044,820 | $190,744,040 | 0% | |
| 2. | 9,275,817 | $160,193,355 | 0% | |
| 3. | 6,022,576 | $104,009,912 | 0.01% | |
| 4. | 4,970,869 | $85,846,908 | 0% | |
| 5. | 4,278,677 | $73,892,752 | 0.01% |
News See All
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2025 Earnings Call Transcript
Operator: Hello, and welcome to Intellia Therapeutics Third Quarter 2025 Financial Results Conference Call. My name is Rocco, and I will be your conference operator today.
Intellia (NTLA) Soars 13% to Fresh High
Earlier this month, Intellia Therapeutics, Inc.
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger 'Buy'
“Rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company’s underlying business.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Intellia Therapeutics Second Quarter 2025 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best CRISPR stocks to buy. Citizens JMP reaffirmed its Market Perform rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) on June 17.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Hedge Fund Resource Center Billionaire Hedge Funds
